NCT04521686 2026-04-22Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT02834013 2026-04-13Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting818 enrolled
NCT04802876 2025-03-21ACROPOLISOLTI Breast Cancer Research GroupPhase 2 Active not recruiting184 enrolled